Pharma giant AstraZeneca has signed a huge deal with a UK start-up to create treatments for diabetes and other autoimmune diseases.
The FTSE 100 firm will team up with London-based Quell Therapeutics to collaborate on research and the licensing of any new medicines.
The aim is to develop treatments for Type 1 diabetes and inflammatory bowel disease through the use of genetically engineered ‘regulatory T-cells’ – ‘Tregs’ for short.
Full story: AstraZeneca in deal with start-up to fight diabetes | This is Money
